Atai Life Sciences N.V. (ATAI)
After hours:
| Previous Close | 1.0400 |
| Open | 1.0800 |
| Bid | 1.1200 x 800 |
| Ask | 1.1400 x 3100 |
| Day's Range | 1.0250 - 1.1500 |
| 52 Week Range | 1.0250 - 3.6500 |
| Volume | |
| Avg. Volume | 598,668 |
| Market Cap | 185.931M |
| Beta (5Y Monthly) | 0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4300 |
| Earnings Date | Nov 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.32 |
GlobeNewswireatai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. Acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two nove
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Trulieve is challenging 280E cannabis taxation, seeking $143 million federal tax refund. TerrAscend raised its full year 2023 guidance, triggering a surge in stock price. Red White & Bloom won the race to acquire Aleafia Health after an earlier stumble. Key Takeaways; Psychedelic Sector Atai strengthened investment in IntelGenx technologies. Awakn’s […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.
- CNW Group
ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT
This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with certain transactions completed by atai Life Sciences AG (Nasdaq: ATAI) ("atai") and IntelGenx Technologies Corp. (the "IntelGenx"), that were previously described in a press release issued by IntelGenx on August 31 2023.
